Europe Bioreactors Market

Europe Bioreactors Market Size (2024 to 2029)

The size of the European Bioreactors Market was valued at USD 342.42 Million in 2024. This value is estimated to be growing at a CAGR of 6.4% to reach USD 466.94 million by 2029 during the forecast period.

Innovative biotechnology solutions and up-gradation in pre-exist facilities are developing the European bioreactor market. Rising chronic disease prevalence, an increase in the incidence of lifestyle diseases like diabetes and cancer, rising biopharmaceutical investments, increasing demand for therapeutically active vaccines, product innovation, and favorable government initiatives to develop healthcare infrastructure are majorly propelling the market growth. Growing personalized medicine market and increasing popularity for them, and increasing the demand for single-use bioreactors among the biopharmaceutical companies will also help the market grow.

On the other hand, regulatory issues regarding single-use bioreactors, limited storage, and vulnerability to leaching may hinder the market's growth. Further, large scale disposal of plastic derivatives is an environmental concern restraining the growth.

This research report on the Europe Bioreactors Market has been segmented and sub-segmented the North America Bioreactors Market into the following categories.

Europe Bioreactors Market Analysis By Material

• Glass
• Stainless-Steel
• Single-use

Europe Bioreactors Market Analysis By Scale

• 5L-20L
• 20L-200L
• 200L-1500L
• Over 1500L

Europe Bioreactors Market Analysis By Production Size

• Lab-Scale Production
• Pilot-Scale Production
• Full-Scale Production

Europe Bioreactors Market Analysis By Control Type

• Manual
• Automated (MFCs)

Europe Bioreactors Market Analysis By End Users

• R&D Departments
• R&D Institutes
• CRO’s
• Biopharmaceutical Companies
• Biopharmaceutical Manufacturers
• CMO’s

By Suppliers

• OEMs
• System Integrators
• EPCs

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European bioreactors market was the second largest region and predicted to occupy the most considerable share in the global market during the forecast period. Private sponsors' funding & government policies and investment in research and development activities are expected to generate new growth possibilities to the bioreactors market in this region. Europe has installed biotechnology & pharmaceutical plants for the production of bioreactors. In Europe, single-use bioreactor demand for new therapeutic drug production in the pharmaceutical industry is raised.

The United Kingdom Bioreactors Market is holding the most significant shares of the market due to the adoption of new technology to develop innovative products. Spain bioreactor manufacturing companies have a robust, comprehensive network connection with other industries. They supply highly integrated modern bioreactors as per the customer's demand. Constant economic growth is also one of the factors for the market to grow. 

Following the UK, the German Bioreactors market is leading to dominant shares of the market. Increasing incidences of chronic diseases and rising demand for quality treatment procedures are evaluating the need for the bioreactor market. Besides, increasing investments in pharmaceutical companies are enhancing the demand for this market.

Promising companies in the Europe Bioreactors Market profiled in this report are Sartorius AG, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, Danaher Corporation, Eppendorf AG, and significant Engineering, Procurement, and Construction (EPC) players included in this report are Amec Foster Wheeler plc., Fluor Corporation, Jacobs Engineering Group Inc., M+W Group, PM Group, and Technip S.A.